Register Login
Register to leave comments
  • News bot July 31, 2026, 12:31 p.m.

    📋 KARYOPHARM THERAPEUTICS INC. (KPTI) - Clinical Trial Update

    Filing Date: 2026-07-31

    Accepted: 2026-07-31 08:30:33

    Event Type: Clinical Trial Update

    Event Details:

    KARYOPHARM THERAPEUTICS INC. (KPTI) Announces Clinical Trial Update KARYOPHARM THERAPEUTICS INC. (KPTI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Specified
    • Collaboration: Wells Avenue

    🔬 Clinical Development Pipeline (KARYOPHARM THERAPEUTICS INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo matching for Selinexor (continuous therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Physician's Choice Treatment Drug Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Selinexor Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Ruxolitinib Other Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Mezigdomide Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Belantamab Mafodotin Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Clarithromycin Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Elotuzumab Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Carfilzomib Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Ixazomib Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Daratumumab Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Bortezomib Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Pomalidomide Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Lenalidomide Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Dexamethasone Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Selinexor (continuous therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Cisplatin (combination therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Dexamethasone (combination therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Gemcitabine (combination therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Rituximab (combination therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Placebo matching for Selinexor (combination therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Selinexor (combination therapy) Drug Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Bone Marrow Aspiration and Biopsy Other Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Biospecimen Collection Other Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Venetoclax Other Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Eltanexor Other Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Matching Placebo for selinexor Other Phase PHASE3 Endometrial Cancer ClinicalTrials.gov
    KPT-330 Other Phase PHASE1 Relapsed Acute Lymphoblastic Leukemia (ALL) ClinicalTrials.gov
    Atezolizumab Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Bevacizumab Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Selinexor Pill Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Paclitaxel Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Carboplatin Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Decitabine Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    dose-escalated selinexor treatment Drug Phase PHASE1 Rectal Neoplasms ClinicalTrials.gov
    standard dose capecitabine Other Phase PHASE1 Rectal Neoplasms ClinicalTrials.gov
    standard dose pelvic radiation therapy Drug Phase PHASE1 Rectal Neoplasms ClinicalTrials.gov
    Pharmacological Study Other Phase PHASE1 Recurrent Squamous Cell Lung Carcinoma ClinicalTrials.gov
    Laboratory Biomarker Analysis Other Phase PHASE1 Recurrent Squamous Cell Lung Carcinoma ClinicalTrials.gov
    Docetaxel Other Phase PHASE1 Recurrent Squamous Cell Lung Carcinoma ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE1 Myeloma Multiple ClinicalTrials.gov
    Cyclophosphamide Other Phase PHASE1 Myeloma Multiple ClinicalTrials.gov
    Bone marrow biopsy Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Cytarabine Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    G-CSF Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Cladribine Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    methotrexate/hydrocortisone/cytarabine Other Phase PHASE1 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Fludarabine Other Phase PHASE1 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Sorafenib Other Phase PHASE1 Leukemia ClinicalTrials.gov
    Idarubicin Other Phase PHASE2 Acute Myeloid Leukemia (Relapsed/Refractory) ClinicalTrials.gov
    Gemcitabine Other Phase PHASE1 B-cell Lymphoma ClinicalTrials.gov
    Cisplatin Other Phase PHASE1 B-cell Lymphoma ClinicalTrials.gov
    Oxaliplatin Other Phase PHASE1 B-cell Lymphoma ClinicalTrials.gov
    Rituximab Other Phase PHASE1 B-cell Lymphoma ClinicalTrials.gov
    Doxorubicin Other Phase PHASE1 Soft Tissue Sarcoma ClinicalTrials.gov
    Irinotecan Other Phase PHASE1 Solid Tumor Malignancy ClinicalTrials.gov
    selinexor (KPT-330) Other Phase PHASE2 Myelodysplastic Syndromes ClinicalTrials.gov
    Folinic Acid Other Phase PHASE1 Colorectal Neoplasm ClinicalTrials.gov
    5-FU Other Phase PHASE1 Colorectal Neoplasm ClinicalTrials.gov
    Ifosfamide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Etoposide Other Phase PHASE1 Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Elotuzumab, Selinexor, and Dexamethasone (ESd) Other Phase PHASE2 Relapsed Multiple Myeloma ClinicalTrials.gov
    Daunorubicin Other Phase PHASE1 Leukemia ClinicalTrials.gov
    Fosaprepitant Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Autologous Hematopoietic Cell Transplantation (HCT) Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Melphalan Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Liposomal doxorubicin Other Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Placebo Other Phase PHASE2 Coronavirus Infection ClinicalTrials.gov
    Verdinexor Other Phase PHASE1 Healthy ClinicalTrials.gov
    Vehicle Gel Other Phase PHASE1 Diabetic Foot Ulcers ClinicalTrials.gov
    Standard-of-Care Other Phase PHASE1 Diabetic Foot Ulcers ClinicalTrials.gov
    Placebo (for selinexor) Other Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Ara-C Other Phase PHASE2 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Hydroxyurea Other Phase PHASE2 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Acetaminophen Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Open Label Selinexor Other Phase PHASE2 Thymoma ClinicalTrials.gov
    Correlative studies Other Phase PHASE1 Recurrent Melanoma ClinicalTrials.gov
    mitoxantrone hydrochloride Other Phase PHASE1 Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities ClinicalTrials.gov
    Methylprednisolone Other Phase PHASE1 Refractory Multiple Myeloma ClinicalTrials.gov
    Tipiracil Other Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    Trifluridine Other Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    KCP-330 Other Phase PHASE1 Sarcoma ClinicalTrials.gov
    Nivolumab Other Phase PHASE1 Solid Tumors ClinicalTrials.gov
    Niacin ER Other Phase PHASE1 Solid Tumors ClinicalTrials.gov
    KPT-9274 Other Phase PHASE1 Solid Tumors ClinicalTrials.gov
    Carmustine Other Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    TTField Other Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Standard Fractionated Radiation therapy (RT) Drug Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Lomustine (CCNU) Other Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Temozolomide (TMZ) Other Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Dexamethasone Oral Other Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Lenalidomide capsule Other Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Bortezomib Injection Other Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Selinexor 20 MG Oral Tablet Other Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Selinexor 60 mg Other Phase PHASE1 Non-Small Cell Lung Carcinoma (NSCLC) ClinicalTrials.gov
    Selinexor 80 mg Other Phase PHASE1 Non-Small Cell Lung Carcinoma (NSCLC) ClinicalTrials.gov
    Selinexor 40 mg Other Phase PHASE1 Non-Small Cell Lung Carcinoma (NSCLC) ClinicalTrials.gov
    FOLFIRI Other Phase PHASE1 Non-Small Cell Lung Carcinoma (NSCLC) ClinicalTrials.gov
    Selinexor 100 mg Other Phase PHASE1 Non-Small Cell Lung Carcinoma (NSCLC) ClinicalTrials.gov
    ASTX727 Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma (RRMM) ClinicalTrials.gov
    KPT-8602 Other Phase PHASE1 Relapsed/Refractory Multiple Myeloma (RRMM) ClinicalTrials.gov
    Ibrutinib Other Phase PHASE1 Prolymphocytic Leukemia ClinicalTrials.gov
    Tafasitamab Other Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Polatuzumab Vedotin Other Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Bendamustine Other Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Momelotinib Other Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Pacritinib Other Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Mesna Other Phase PHASE2 Lymphoma ClinicalTrials.gov
    Methotrexate Other Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Filgrastim Other Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Isatuximab SC Wearable Injection System DEVICE Phase PHASE1 Relapse Multiple Myeloma ClinicalTrials.gov
    Isatuximab DRUG Phase PHASE1 Relapse Multiple Myeloma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: KARYOPHARM THERAPEUTICS INC.
    • Ticker Symbol: KPTI

Search

News categories